Rs 1,000 profit in Rs 4,500 per coronavirus test; Thyrocare debunks demand for higher price
Dr A Velumani, chairman, CEO and MD of Thyrocare Technologies says the mantra to his ability to turn the Rs 4,500 a test into a viable and profitable exercise was his dependence on volumes
May lower COVID-19 testing fee in the next 10 days: Thyrocare CEO A Velumani
The company has announced that it will conduct coronavirus testing on a zero-profit basis for the next one year. Thyrocare Technologies Ltd - 539871 - Announcement under Regulation 30 (LODR)-Strikes /Lockouts / Disturbances
We wish to intimate that as the Government of India has invoked the provisions of the National Disaster Management Act, 2005, to combat the spread of COVID-19, as a precautionary measure to ensure safety of our patients and our staffs, the PET-CT Scanning Operations at our selective Centres managed/ operated by our wholly-owned subsidiary, Nueclear Healthcare Limited, have been temporarily suspended. This is for your information Thyrocare Technologies Ltd - 539871 - Closure of Trading Window
This is to inform you that pursuant to the provisions of SEBI (Prohibition of Insider Trading) Regulations 2015, as amended, and in accordance with the Company's Code relating to prohibition of insider trading, the trading window of the Company will remain closed for trading in Company's equity shares for Directors / Designated Employees / Connected Persons covered by the said Code, with immediate effect, i.e. from April 01, 2020 and would be re-opened after 48 hours of date of announcement / declaration of Audited Financial Results for the Quarter and Year ended March 31, 2020. We request you to please take the same on record. Thyrocare Technologies Ltd - 539871 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that we would be having con-calls with the representatives of the following organisations to discuss the impact of COVID-19: i) ICICI Prudential AMC, at 02.30 P.M., today, i.e. Tuesday, March 31, 2020. ii) Premji Invest, at 03.30 P.M., today, i.e. Tuesday, March 31, 2020. iii) Nippon India Mutual Fund, at 04.00 P.M. on Wednesday, April 01, 2020. Please note that these are subject to any last minute changes. Healthcare firms offer home tests, free virtual doctor services
Facility is made available through tie-ups with government-approved labs like Thyrocare and Metropolis Thyrocare Technologies Ltd - 539871 - Announcement Under Regulation 29 (1) Of The SEBI (SAST) Regulations, 2011
This is to inform you that pursuant to the Regulation 29 (1) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, we have received communication from Nalanda India Equity Fund Limited, intimating acquisition of 33,66,371 Nos. of equity shares from the open market, representing 6.37% of paid up capital of the Company. A copy of their letter along with detailed information as specified in the Format of Regulation 29 (1) of the SEBI (SAST) Regulations, 2011, is enclosed herewith. Thyrocare Technologies Ltd - 539871 - Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Nalanda India Equity Fund Ltd Quarantined passengers reluctant to take COVID-19 test, rural areas lack labs, says Thyrocare chief
Velumani is concerned about people living in rural areas as most of the labs are based in metropolitan cities. Quarantined passengers, symptomatic patients refusing tests due to stigma, high cost: Thyrocare founder
Testing a challenge in remote rural areas